| Literature DB >> 36114524 |
Chenyan Guo1,2, Xiang Tao1,2, Lihong Zhang1,2, Ying Zhang1,2, Keqin Hua1,2, Junjun Qiu3,4.
Abstract
BACKGROUND: Considering the unique biological behavior of cervical adenocarcinoma (AC) compared to squamous cell carcinoma, we now lack a distinct method to assess prognosis for AC patients, especially for intermediate-risk patients. Thus, we sought to establish a Silva-based model to predict recurrence specific for the intermediate-risk AC patients and guide adjuvant therapy.Entities:
Keywords: Cervical adenocarcinoma; Prediction model; Recurrence; Silva
Mesh:
Year: 2022 PMID: 36114524 PMCID: PMC9482255 DOI: 10.1186/s12905-022-01971-z
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.742
Comparison of clinic-pathological factors between different Silva patterns
| Characteristics | Pattern A (N = 96) | Pattern B (N = 90) | Pattern C (N = 159) | |
|---|---|---|---|---|
| Age | 0.053 | |||
| Mean ± SD | 44.8 ± 9.9 | 45.7 ± 8.9 | 47.8 ± 10.6 | |
| FIGO stage (%) | < 0.001 | |||
| Stage 1 | 93 (96.9) | 86 (95.6) | 130 (81.8) | |
| Stage 2 | 3 (3.1) | 4 (4.4) | 29 (18.2) | |
| Comorbidity (%) | 0.904 | |||
| No | 85 (88.5) | 78 (86.7) | 138 (86.8) | |
| Yes | 11 (11.5) | 12 (13.3) | 21 (13.2) | |
| Adjuvant treatment (%) | < 0.001 | |||
| No | 69 (71.9) | 42 (46.7) | 32 (65.9) | |
| Yes | 27 (28.1) | 48 (53.3) | 127 (79.9) | |
| HPV infect (%) | 0.004 | |||
| No | 1 (1) | 2 (2.2) | 9 (5.7) | |
| Yes | 29 (30.2) | 41 (45.6) | 39 (24.5) | |
| Unknown | 66 (68.8) | 47 (52.2) | 111 (69.8) | |
| LEEP (%) | 0.403 | |||
| No | 91 (94.8) | 85 (94.4) | 155 (97.5) | |
| Yes | 5 (5.2) | 5 (5.6) | 4 (2.5) | |
| Surgical approach (%) | 0.033 | |||
| Laparoscopy | 88 (91.7) | 86 (95.6) | 136 (85.5) | |
| Laparotomy | 8 (8.3) | 4 (4.4) | 23 (14.5) | |
| Surgical duration, min (%) | 0.23 | |||
| ≤ 200 | 50 (52.1) | 56 (62.2) | 82 (51.6) | |
| > 200 | 46 (47.9) | 34 (37.8) | 77 (48.4) | |
| Blood loss, ml (%) | 0.943 | |||
| ≤ 200 | 51 (53.1) | 49 (54.4) | 83 (52.2) | |
| > 200 | 45 (46.9) | 41 (45.6) | 76 (47.8) | |
| Transfusion (%) | 0.186 | |||
| No | 93 (96.9) | 82 (91.1) | 145 (91.2) | |
| Yes | 3 (3.1) | 8 (8.9) | 14 (8.8) | |
| LN metastasis (%) | < 0.001 | |||
| No | 94 (97.9) | 85 (94.4) | 109 (68.6) | |
| Yes | 2 (2.1) | 5 (5.6) | 50 (31.4) | |
| Metastasis site (%) | < 0.001 | |||
| No | 94 (97.9) | 85 (94.4) | 109 (68.6) | |
| Pelvic LN | 2 (2.1) | 5 (5.6) | 32 (20.1) | |
| Common iliac LN | 0 (0) | 0 (0) | 15 (9.4) | |
| Para-aortic LN | 0 (0) | 0 (0) | 3 (1.9) | |
| Surgical margin (%) | 0.043 | |||
| No | 94 (97.9) | 89 (98.9) | 148 (93.1) | |
| Yes | 2 (2.1) | 1 (1.1) | 11 (6.9) | |
| Parametrial invasion (%) | < 0.001 | |||
| No | 96 (100) | 89 (98.9) | 140 (88.1) | |
| Yes | 0 (0) | 1 (1.1) | 19 (11.9) | |
| Tumor size, cm (%) | < 0.001 | |||
| ≤ 2 | 72 (75) | 50 (55.6) | 32 (20.1) | |
| (2,4) | 23 (24) | 33 (36.7) | 90 (56.6) | |
| > 4 | 1 (1) | 7 (7.8) | 37 (23.3) | |
| LVSI (%) | < 0.001 | |||
| No | 96 (100) | 67 (74.4) | 63 (39.6) | |
| Mild | 0 (0) | 22 (24.4) | 56 (35.2) | |
| Substantial | 0 (0) | 1 (1.1) | 40 (25.2) | |
| DSI (%) | < 0.001 | |||
| No | 28 (29.2) | 10 (11.1) | 12 (7.5) | |
| < 2/3 | 61 (63.5) | 55 (61.1) | 27 (17) | |
| ≥ 2/3 | 7 (7.3) | 25 (27.8) | 120 (75.5) | |
| PNI (%) | 0.002 | |||
| No | 96 (100) | 87 (96.7) | 143 (89.9) | |
| Yes | 0 (0) | 3 (3.3) | 16 (10.1) |
Fig. 1Survival outcome comparison according to different Silva patterns
Univariate Cox analysis in 345 AC patients
| Characteristics | Univariate Cox analysis (RFS) | Univariate Cox analysis (OS) | ||
|---|---|---|---|---|
| HR (95%CI) | HR (95%CI) | |||
| Age | 0.009 | 0.047 | ||
| Mean ± SD | 1.044 [1.011, 1.079] | 2.152 [1.011, 4.58] | ||
| FIGO stage (%) | < 0.001 | 0.003 | ||
| Stage 1 | 1 | 1 | ||
| Stage 2 | 3.98 [1.839, 8.611] | 3.754 [1.584, 8.899] | ||
| Silva (%) | < 0.001 | 0.002 | ||
| Type A | 1 | 1 | ||
| Type B | 3.282 [0.341, 31.556] | 3.279 [0.341, 31.531] | ||
| Type C | 18.936 [2.576, 139.2] | 15.472 [2.089, 114.607] | ||
| Comorbidity (%) | 0.289 | 0.373 | ||
| No | 1 | 1 | ||
| Yes | 1.616 [0.665, 3.928] | 1.555 [0.589, 4.108] | ||
| Adjuvant treatment (%) | 0.012 | 0.026 | ||
| No | 1 | 1 | ||
| Yes | 3.11 [1.28, 7.557] | 3.017 [1.142, 7.967] | ||
| LEEP (%) | 0.703 | 0.443 | ||
| No | 1 | 1 | ||
| Yes | 0.679 [0.093, 4.974] | 0.046 [0, 119.3] | ||
| Surgical approach (%) | 0.019 | 0.008 | ||
| Laparoscopy | 1 | 1 | ||
| Laparotomy | 2.623 [1.169, 5.89] | 3.097 [1.344, 7.134] | ||
| Surgical duration, min (%) | 0.914 | 0.226 | ||
| ≤ 200 | 1 | 1 | ||
| > 200 | 0.962 [0.478, 1.936] | 0.616 [0.281, 1.35] | ||
| Blood loss, ml (%) | 0.975 | 0.996 | ||
| ≤ 200 | 1 | 1 | ||
| > 200 | 0.989 [0.49, 1.995] | 0.998 [0.465, 2.14] | ||
| Transfusion (%) | 0.015 | 0.005 | ||
| No | 1 | 3.66 [1.475, 9.084] | ||
| Yes | 3.024 [1.241, 7.37] | |||
| LN metastasis (%) | < 0.001 | < 0.001 | ||
| No | 1 | 1 | ||
| Yes | 5.94 [2.969, 11.885] | 8.349 [3.873, 17.997] | ||
| LN metastasis site (%) | < 0.001 | < 0.001 | ||
| No | 1 | 1 | ||
| Pelvic | 2.956 [1.156, 7.557] | 4.254 [1.573, 11.506] | ||
| Common iliac | 15.596 [6.873, 35.388] | 20.178 [8.35, 48.762] | ||
| Para-aortic | 12.111 [1.587, 92.455] | 17.452 [2.178, 139.82] | ||
| Surgical margin (%) | 0.001 | < 0.001 | ||
| No | 1 | 1 | ||
| Yes | 5.307 [2.041, 13.798] | 7.697 [3.105, 19.078] | ||
| Parametrial invasion (%) | < 0.001 | < 0.001 | ||
| No | 1 | 1 | ||
| Yes | 5.516 [2.383, 12.768] | 6.493 [2.743, 15.369] | ||
| Tumor size, cm (%) | 0.001 | 0.002 | ||
| ≤ 2 | 2.198 [0.895, 5.396] | 1 | ||
| (2,4) | 5.834 [2.217, 15.354] | 1.556 [0.603, 4.016] | ||
| > 4 | 5.355 [1.991, 14.406] | |||
| LVSI (%) | < 0.001 | < 0.001 | ||
| No | 1 | 14.675 [4.176, 51.57] | ||
| Mild | 13.207 [4.411, 39.544] | 25.267 [7.034, 90.757] | ||
| Substantial | 21.02[6.768,65.285] | |||
| DSI (%) | < 0.001 | < 0.001 | ||
| < 2/3 | 1 | 1 | ||
| ≥ 2/3 | 20.369 [4.868, 85.236] | 7.463 [2.581, 21.581] | ||
| PNI (%) | 0.005 | 0.001 | ||
| No | 1 | 1 | ||
| Yes | 3.955 [1.519, 10.293] | 4.898 [1.848, 12.981] | ||
Significant intermediate risk factors in 254 intermediate-risk AC patients
| Intermediate risk factors | Univariate Cox Analysis | Multivariate Cox Analysis | ||
|---|---|---|---|---|
| HR, 95%CI | HR, 95%CI | |||
| Silva B + C | 7.281 [0.946, 56.036] | 0.057 | 1.194 [0.101, 14.093] | 0.888 |
| Silva C | 5.455 [1.677, 17.746] | 0.005 | 1.501 [0.411, 5.486] | 0.539 |
| ≥ 3 cm | 4.252 [1.391, 13] | 0.011 | 2.141 [0.672, 6.823] | 0.198 |
| ≥ 3.5 cm | 3.212 [1.079, 9.562] | 0.036 | 0.685 [0.137, 3.435] | 0.646 |
| DSI > 2/3 | 11.453 [2.538, 51.68] | 0.002 | 7.696 [1.598, 37.051] | 0.011 |
| > mild LVSI | 6.24 [2.018, 19.292] | 0.001 | 3.185 [0.98, 10.356] | 0.054 |
Four-factor model performance comparison
| Univariate Cox Analysis | Log-rank test | C index | 95%CI | ||||
|---|---|---|---|---|---|---|---|
| Models | HR | 95% CI | Chi-Square | ||||
| Sedlis Criteria | 0.002 | 6.137 | 2–18.833 | 13.083 | 0.000 | 0.702 | 0.597–0.78 |
| Four-factor Model: Tumor size, DSI, LVSI, Silva | |||||||
| Silva B + C, ≥ 3 cm, DSI > 2/3, > mild LVSI | 0.008 | 16.028 | 2.083–123.36 | 12.964 | 0.000 | 0.752 | 0.676–0.804 |
| Silva C, ≥ 3 cm, DSI > 2/3, > mild LVSI | 0.005 | 6.507 | 1.787–23.694 | 10.684 | 0.001 | 0.715 | 0.606–0.798 |
| Silva B + C, ≥ 3.5 cm, DSI > 2/3, > mild LVSI | 0.007 | 16.676 | 2.166–128.37 | 13.55 | 0.000 | 0.756 | 0.676–0.809 |
| Silva C, ≥ 3.5 cm, DSI > 2/3, > mild LVSI | 0.005 | 6.507 | 1.787–23.694 | 10.684 | 0.001 | 0.715 | 0.606–0.798 |
| Silva B + C, ≥ 3 cm, DSI > 2/3, > mild LVSI | 0.001 | 7.714 | 2.37–25.105 | 16.07 | 0.000 | 0.734 | 0.640–0.837 |
| Silva C, ≥ 3 cm, DSI > 2/3, > mild LVSI | < 0.001 | 10.792 | 3.31–35.19 | 24.262 | 0.000 | 0.761 | 0.670–0.862 |
| Silva B + C, ≥ 3.5 cm, DSI > 2/3, > mild LVSI | 0.001 | 6.321 | 2.059–19.402 | 13.621 | 0.000 | 0.706 | 0.595–0.799 |
| Silva C, ≥ 3.5 cm, DSI > 2/3, > mild LVSI | < 0.001 | 9.445 | 3.065–29.101 | 22.696 | 0.000 | 0.735 | 0.626–0.830 |
| Silva B + C, ≥ 3 cm, DSI > 2/3, > mild LVSI | < 0.001 | 8.526 | 2.768–26.263 | 20.084 | 0.000 | 0.659 | 0.554–0.804 |
| Silva C, ≥ 3 cm, DSI > 2/3, > mild LVSI | < 0.001 | 8.143 | 2.502–26.505 | 17.267 | 0.000 | 0.631 | 0.525–0.764 |
| Silva B + C, ≥ 3.5 cm, DSI > 2/3, > mild LVSI | 0.001 | 7.251 | 2.223–23.645 | 14.792 | 0.000 | 0.627 | 0.523–0.770 |
| Silva C, ≥ 3.5 cm, DSI > 2/3, > mild LVSI | 0.005 | 6.46 | 1.776–23.493 | 10.632 | 0.001 | 0.597 | 0.519–0.696 |
Fig. 2Four-factor model performance comparison